CureVac Earnings Reports

CureVac achieved a net profit of €273.2 million in Q3 2025, mainly due to a €370 million settlement gain and a €50 million license amendment payment. While revenue fell drastically year-over-year without a repeat of last year's GSK payment, strategic cost management and restructuring efforts supported profitability.

CureVac posted a net loss in Q4 2024 but maintained a solid cash position of €481.7 million. Revenue decreased year-over-year, impacted by prior one-off events. The company continues to focus on oncology and prophylactic vaccine R&D, bolstered by strategic milestones and litigation successes.